ArticleMolecular pharmaceutics2014
The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma.
Article in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 87 citations in OpenAlex.
- Repurposing Niflumic Acid-Loaded PEGylated Cerosomes for Topical Solid Ehrlich's Carcinoma Management via EGFR/ERK/miR-21 Signaling Pathway Modulation.Pharmaceutics · 2026Article
- Curcumin as a ceramide metabolism-targeting agent: Molecular mechanisms and therapeutic implications in cancer.Molecular biology reports · 2026Review
- Curcumin-based biocompatible nanocarriers: a contemporary perspective in functional foods and biomedical applications.Discover nano · 2025Review
- Curcumin/pEGCG-encapsulated nanoparticles enhance spinal cord injury recovery by regulating CD74 to alleviate oxidative stress and inflammation.Journal of nanobiotechnology · 2024Article
- Review
- Therapeutic Potential of Ceramide in Cancer Treatment.Journal of cancer research and oncobiology · 2024Article
- Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.Journal of nanobiotechnology · 2023Review
- Curcumin and its Analogs and Carriers: Potential Therapeutic Strategies for Human Osteosarcoma.International journal of biological sciences · 2023Review
- Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment.Frontiers in oncology · 2022Review
- The Multifaceted Therapeutic Mechanisms of Curcumin in Osteosarcoma: State-of-the-Art.Journal of oncology · 2021Review
- Curcumin: reclaiming the lost ground against cancer resistance.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Use of nanosystems to improve the anticancer effects of curcumin.Beilstein journal of nanotechnology · 2021Review
- Properties, Extraction Methods, and Delivery Systems for Curcumin as a Natural Source of Beneficial Health Effects.Medicina (Kaunas, Lithuania) · 2020Review
- Recent advances of drug delivery nanocarriers in osteosarcoma treatment.Journal of Cancer · 2020Review
- Curcumin Encapsulated PEGylated Nanoliposomes: A Potential Anti-Infective Therapeutic Agent.Indian journal of microbiology · 2019Article
- Liposome-Encapsulated Curcumin-Loaded 3D Printed Scaffold for Bone Tissue Engineering.ACS applied materials & interfaces · 2019Article
- Clusters of Nanoscale Liposomes Modulate the Release of Encapsulated Species and Mimic the Compartmentalization Intrinsic in Cell Structures.ACS applied nano materials · 2019Article
- Hydrophobic Drug-Loaded PEGylated Magnetic Liposomes for Drug-Controlled Release.Nanoscale research letters · 2017Article
- Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems.Pharmaceutics · 2017Review
- Engineering Remotely Triggered Liposomes to Target Triple Negative Breast Cancer.Oncomedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
This study examines the antitumor potential of curcumin and C6 ceramide (C6) against osteosarcoma (OS) cell lines when both are encapsulated in the bilayer of liposomal nanoparticles. Three liposomal formulations were prepared: curcumin liposomes, C6 liposomes and C6-curcumin liposomes. Curcumin in combination with C6 showed 1.5 times enhanced cytotoxic effect in the case of MG-63 and KHOS OS cell lines, in comparison with curcumin liposomes alone. Importantly, C6-curcumin liposomes were found to be less toxic on untransformed primary human cells (human mesenchymal stem cells) in comparison to OS cell lines. In addition, cell cycle assays on a KHOS cell line after treatment revealed that curcumin only liposomes induced G2/M arrest by upregulation of cyclin B1, while C6 only liposomes induced G1 arrest by downregulation of cyclin D1. C6-curcumin liposomes induced G2/M arrest and showed a combined effect in the expression levels of cyclin D1 and cyclin B1. The efficiency of the preparations was tested in vivo using a human osteosarcoma xenograft assay. Using pegylated liposomes to increase the plasma half-life and tagging with folate (FA) for targeted delivery in vivo, a significant reduction in tumor size was observed with C6-curcumin-FA liposomes. The encapsulation of two water insoluble drugs, curcumin and C6, in the lipid bilayer of liposomes enhances the cytotoxic effect and validates the potential of combined drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.